Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functional Constipation BETHESDA, Md., Oct. 8, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), today announced clinical data showing that lubiprostone is efficacious and well tolerated in...

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at BioCentury(R) NewsMakers in the Biotech Industry 2013 Conference BETHESDA, Md., Sept. 20, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...

Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology BETHESDA, Md., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Sucampo AG ("SAG"), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), announced today that it will present four...

Sucampo Announces Positive Top-Line Results in Phase 1a Trials of Cobiprostone and SPI-3608 BETHESDA, Md., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (Sucampo) today announced the positive top-line results of two recently completed clinical trials, a Phase...